US · Healthcare · Biotechnology
EPS came in at -1.22 against a street estimate of -1.26 — a beat of 3.2%.
Analysts rate Ideaya Biosciences Inc a strong buy (15 buy, 1 hold, 0 sell out of 16) with an average price target of $51.54.
| Fund | Stake |
|---|---|
| FMR Inc | 14.62% |
| BlackRock Inc | 9.22% |
| Jupiter Topco LLC | 8.89% |
| Capital Research Global Investors | 5.54% |
| Baker Bros Advisors LP | 5.19% |
| State Street Corp | 4.71% |
| Vanguard Capital Management, LLC | 4.28% |
| Logos Global Management LP | 3.11% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $10.242 million, down from $207.834 million in the third quarter of 2025. • Nine-month 2026 revenu | 2026-11-03 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 collaboration revenue was $10.2 million, compared with $8.9 million in Q2 2026. • Q3 2026 net loss was $125.7 million, or | 2026-11-03 |
| Quarterly report · Q2 2026 IDEAYA BIOSCIENCES, INC. – FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash & Securities Position: $1.24 billion in cash, | 2026-08-04 |
| Results announced · Q3 2026 IDEAYA BIOSCIENCES Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $1.24 billion in cash, cash equivalents, and marketable secur | 2026-08-04 |
| Shareholder vote results · Q2 2026 IDEAYA BIOSCIENCES, INC. (IDYA) — 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 16, 2026 • 87,860,920 common shares outstanding as of reco | 2026-06-23 |
| Company announcement · Q2 2026 IDEAYA BIOSCIENCES, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company completed a public offering on June 10, 2026, raising net proceeds of approximatel | 2026-06-10 |
| Company announcement · Q2 2026 IDEAYA BIOSCIENCES, INC. - 8-K SUMMARY (June 3, 2026) BUSINESS & SEGMENT HIGHLIGHTS • IDEAYA announced a clinical collaboration with F. Hoffmann-La | 2026-06-03 |
| Quarterly report · Q1 2026 IDEAYA BIOSCIENCES, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and marketable securities: $972.9 million as of March 31, 2026 (down from $9 | 2026-05-05 |
Readable in the app.
| Announcement | Date |
|---|---|
| Clinical collaboration with Roche to evaluate combination therapy in pancreatic cancer IDEAYA Biosciences announced positive results from its OptimUM-02 trial testing darovasertib (combined with crizotinib) for metastatic uveal melanoma. The drug met its primary endpoint, show | 2026-08-04 |
| Clinical collaboration with Roche to evaluate combination therapy IDEAYA Biosciences announced a clinical collaboration with Roche on June 3, 2026, to study IDE892 (IDEAYA's PRMT5 inhibitor) combined with RG6505 (Roche's pan-RAS inhibitor) in pancreatic ca | 2026-06-03 |
| Phase 2/3 trial met primary endpoint; NDA filing targeted H2 2026 IDEAYA Biosciences announced that its Phase 2/3 OptimUM-02 trial of darovasertib (combined with crizotinib) met its primary endpoint for treating first-line HLA*A2-negative metastatic uveal | 2026-05-05 |
| Clinical collaboration agreement with AstraZeneca for combination therapy evaluation IDEAYA Biosciences announced a clinical collaboration agreement with AstraZeneca on April 8, 2026. Under the deal, IDEAYA will sponsor a global Phase 1 clinical trial testing its experimenta | 2026-04-09 |
| Phase 2/3 trial topline results expected by end of March 2026 IDEAYA Biosciences reported strong clinical progress with several key milestones. The company's lead program, darovasertib combined with crizotinib for metastatic uveal melanoma (mUM), compl | 2026-02-17 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ideaya Biosciences Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.